Aprea Therapeutics Gets Nasdaq Extension for Minimum Bid Price Compliance

Aprea Therapeutics, Inc. received a notification from Nasdaq granting an additional 180-day period, until January 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. This is a second compliance period, following an initial period that ended on July 22, 2026, during which the company did not regain compliance. To meet the requirement, the common stock's closing bid price must be at least $1.00 for a minimum of 10 consecutive business days. Failure to comply by the deadline could lead to delisting.